Amyotrophic Lateral Sclerosis (ALS)

Searching for Signs

The 61st annual meeting of the American Academy of Neurology (AAN), held in Seattle April 25-May 2, included several ALS-related presentations.

ALS: A Vicious Cycle

A vicious cycle in which damage to nerve cells (neurons) in the spinal cord results in the loss of an important mechanism to protect neurons, causing more neuron loss, has been identified as a possible contributor to ALS (amyotrophic lateral sclerosis). Identification of this pathway opens the door to targeting it with therapeutic agents.

ALS: A Vicious Cycle

A vicious cycle in which damage to nerve cells (neurons) in the spinal cord results in the loss of an important mechanism to protect neurons, causing more neuron loss, has been identified as a possible contributor to ALS (amyotrophic lateral sclerosis). Identification of this pathway opens the door to targeting it with therapeutic agents.

Silencing Toxic Genes

A new gene therapy approach to "silencing" disease-causing genetic information has been developed by researchers at Rutgers University in Piscataway, N.J., and Integrated DNA Technologies in Coralville, Ia.

Silencing Toxic Genes

A new gene therapy approach to "silencing" disease-causing genetic information has been developed by researchers at Rutgers University in Piscataway, N.J., and Integrated DNA Technologies in Coralville, Ia.

ALS Fatigue Fighter

Study results reported in the March 2009 issue of Muscle & Nerve indicate that modafinil (marketed under the brand name Provigil) "may be a promising intervention for fatigue in ALS (amyotrophic lateral sclerosis) patients." Fatigue and daytime sleepiness often accompany this disease.

Hiroshi Mitsumoto, director of the Eleanor and Lou Gehrig MDA/ALS Research Center at Columbia University Medical Center in New York, where the study was based, received MDA support to conduct it.

ALS Fatigue Fighter

Study results reported in the March 2009 issue of Muscle & Nerve indicate that modafinil (marketed under the brand name Provigil) "may be a promising intervention for fatigue in ALS (amyotrophic lateral sclerosis) patients." Fatigue and daytime sleepiness often accompany this disease.

Hiroshi Mitsumoto, director of the Eleanor and Lou Gehrig MDA/ALS Research Center at Columbia University Medical Center in New York, where the study was based, received MDA support to conduct it.

Experts Discuss ALS

Nearly 600 conferees gathered in Las Vegas Jan. 25-28 for the 2009 MDA National Clinic Directors Conference, where a number of experts presented a broad range of topics covering neuromuscular disease.

One particular area of focus was ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease). Highlights included discussions of cognitive difficulties, immunization strategies in certain of the familial forms of the disease, and stem cells as possible therapy.

Experts Discuss ALS

Nearly 600 conferees gathered in Las Vegas Jan. 25-28 for the 2009 MDA National Clinic Directors Conference, where a number of experts presented a broad range of topics covering neuromuscular disease.

One particular area of focus was ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease). Highlights included discussions of cognitive difficulties, immunization strategies in certain of the familial forms of the disease, and stem cells as possible therapy.

Abnormal behavior in ALS may deserve closer look

Stem Cell Research: Major Step

The U.S. Food and Drug Administration (FDA) has said yes to a small safety trial of nervous-system stem cells in people with recently sustained injuries to the middle (thoracic) part of the spinal cord, the biopharmaceutical company Geron Corporation of Menlo Park, Calif., announced Jan. 23, 2009.

Pages